Last updated 16 days ago

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

1063 patients around the world
Available in Argentina, Mexico
Eli Lilly and Company
5Research sites
1063Patients around the world
This study is for people with
Ulcerative colitis
Moderate/severe ulcerative colitis
Requirements for the patient
To 80 Years
All Gender
Medical requirements
Sites
CER Instituto Médico - Quilmes, Buenos Aires
CER Instituto Médico - Quilmes, Buenos Aires
Recruiting
Av. Vicente Lopez 1441, Quilmes, Buenos Aires
Instituto de Investigaciones Clínicas Quilmes
Instituto de Investigaciones Clínicas Quilmes
Recruiting
Sarmiento 315, Quilmes, Buenos Aires, Argentina
Glenny Corp S.A.
Recruiting
Ruiz Huidobro 4693, CABA, Buenos Aires
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Italia 428, Rosario - Santa Fe
Mautalen - Salud e Investigación - CABA
Recruiting
Azcuénaga 1860, CABA, Buenos Aires
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy